Tags

Type your tag names separated by a space and hit enter

Breast carcinomas expressing basal markers have poor clinical outcome regardless of estrogen receptor status.
Oncol Rep. 2008 Mar; 19(3):617-25.OR

Abstract

To evaluate the clinical significance of gene expression-based classification and define the characteristic features of the new basal-like subtype, invasive breast carcinomas were divided into ER, HER2, basal-like and null subtypes by immunohistochemical analysis. A total of 401 invasive breast carcinomas were submitted to tissue microarray and stained with ER, HER2, EGFR, c-KIT and cytokeratin (CK) 5/6. The basal-like tumors, defined as positive for one or more basal markers but negative for both ER and HER2, comprised 18.5%. They were larger (p=0.041), showed higher grade (p<0.001), and more frequently expressed p53 (p=0.003). Expression of the basal marker itself showed negative prognostic effect, particularly in node-positive group. Even ER-positive patients had far shorter disease-free survival (DFS) when the tumor coexpressed one or more basal marker (p<0.001). Discrimination of basal-like subtype or tumors positive for basal markers may be clinically significant also in the treatment and prognosis of breast carcinomas.

Authors+Show Affiliations

Department of Pathology, Korea University Guro Hospital, Seoul 152-703, Korea.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

18288392

Citation

Shin, Bong Kyung, et al. "Breast Carcinomas Expressing Basal Markers Have Poor Clinical Outcome Regardless of Estrogen Receptor Status." Oncology Reports, vol. 19, no. 3, 2008, pp. 617-25.
Shin BK, Lee Y, Lee JB, et al. Breast carcinomas expressing basal markers have poor clinical outcome regardless of estrogen receptor status. Oncol Rep. 2008;19(3):617-25.
Shin, B. K., Lee, Y., Lee, J. B., Kim, H. K., Lee, J. B., Cho, S. J., & Kim, A. (2008). Breast carcinomas expressing basal markers have poor clinical outcome regardless of estrogen receptor status. Oncology Reports, 19(3), 617-25.
Shin BK, et al. Breast Carcinomas Expressing Basal Markers Have Poor Clinical Outcome Regardless of Estrogen Receptor Status. Oncol Rep. 2008;19(3):617-25. PubMed PMID: 18288392.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Breast carcinomas expressing basal markers have poor clinical outcome regardless of estrogen receptor status. AU - Shin,Bong Kyung, AU - Lee,Youngseok, AU - Lee,Jung Bok, AU - Kim,Han Kyeom, AU - Lee,Jae Bok, AU - Cho,Su Jin, AU - Kim,Aeree, PY - 2008/2/22/pubmed PY - 2008/5/21/medline PY - 2008/2/22/entrez SP - 617 EP - 25 JF - Oncology reports JO - Oncol Rep VL - 19 IS - 3 N2 - To evaluate the clinical significance of gene expression-based classification and define the characteristic features of the new basal-like subtype, invasive breast carcinomas were divided into ER, HER2, basal-like and null subtypes by immunohistochemical analysis. A total of 401 invasive breast carcinomas were submitted to tissue microarray and stained with ER, HER2, EGFR, c-KIT and cytokeratin (CK) 5/6. The basal-like tumors, defined as positive for one or more basal markers but negative for both ER and HER2, comprised 18.5%. They were larger (p=0.041), showed higher grade (p<0.001), and more frequently expressed p53 (p=0.003). Expression of the basal marker itself showed negative prognostic effect, particularly in node-positive group. Even ER-positive patients had far shorter disease-free survival (DFS) when the tumor coexpressed one or more basal marker (p<0.001). Discrimination of basal-like subtype or tumors positive for basal markers may be clinically significant also in the treatment and prognosis of breast carcinomas. SN - 1021-335X UR - https://www.unboundmedicine.com/medline/citation/18288392/Breast_carcinomas_expressing_basal_markers_have_poor_clinical_outcome_regardless_of_estrogen_receptor_status_ L2 - http://www.spandidos-publications.com/or/19/3/617 DB - PRIME DP - Unbound Medicine ER -